Empagliflozin for Cardiovascular Disease (EMPA-HEART 2 Trial)

"To date, there are 49 ongoing studies for Empagliflozin in 43 nations and 237 cities. This drug was first trialed by Boehringer Ingelheim back in 2018 with 175 participants and successfully attained Phase 3 approval status. Since then, an impressive 18,466 trials have been finished."

"Empagliflozin is the drug of choice for helping patients with cardiovascular diseases. Additionally, it has been show to reduce mortality from heart failure and diabetes mellitus type 2 (T2DM)."

"Affirmative. Records on clinicaltrials.gov confirm that this medical research is currently enrolling individuals, with the initial posting taking place on April 1st 2021 and the most recent edit occurring on June 14th 2021. This investigation requires 164 people to be recruited from 3 distinct locations."

"Yes, the information available on clinicaltrials.gov shows that this experiment is currently searching for participants. It was first posted in April 1st 2021 and has been revised more recently on June 14th of the same year. The trial requires 164 volunteers across 3 locations to be completed successfully."

"Patients who are aged between 40 and 80 qualify to be enrolled in this trial."

"Currently, 49 clinical trials for Empagliflozin are in operation with 13 of them being Phase 3. The primary testing location is Quilmes, Maryland, though other research sites exist across the country and total 1,012."

"Through our assessment at Power, we have determined that Empagliflozin is safe enough to receive a score of 3. This conclusion was made due to it being approved for use in Phase 4 clinical trials."

"This clinical trial seeks 164 cardiovascular disease sufferers aged 40-80 to participate. To be eligible, participants must possess ECG evidence of LV hypertrophy as per the Sokolow-Lyon criteria and be willing to comply with scheduled visits and treatments. They also need an increased LVMi ≥96g/m2 for women and ≥116g/m2 for men (as calculated by echocardiogram or cMRI), structural heart disease defined as interventricular septal thickness or posterior wall thickness at end-diastole of ≥11 mm (as measured by 2D echocardiography or"